Related Experiment Video
Updated: May 12, 2026

Fission Yeast as a Platform for Antibacterial Drug Screens Targeting Bacterial Cytoskeleton Proteins
Published on: April 26, 2024
Yeast as a biosensor of detoxification: a tool for identifying new compounds that revert multidrug resistance
Carmen Martín-Cordero1, Angeles Sanchez-Pico, Antonio J Leon-Gonzalez
1Centro Andaluz de Biologia del Desarrollo, Universidad Pablo de Olavide-Consejo Superior de Investigaciones Cientificas, Junta de Andalucia Ctra. Utrera Km1 41013 Sevilla, Spain. rroddag@upo.es
Abstract:
During tumour progression, cells accumulate secondary mutations and/or chromosomal aberrations that generate genetic diversity within the tumour cell population. This may result in the acquisition of new properties that increase tumour malignancy, such as invasiveness or resistance to chemotherapy. One of the important mechanisms of chemotherapy resistance is overexpression or biochemical activation of ABC family transporters. ABC transporters remove anti tumour drugs from the cell, reducing their intracellular concentration and producing resistance against a wide range of chemically unrelated drugs, known as multidrug resistant phenotype (MDR). During recent decades, much effort has been devoted to the isolation of compounds able to inhibit the activity of these transporters. However, few such compounds have reached clinical practice and MDR remains a serious complication in cancer therapy. In an innovative approach to finding new ABC inhibitors, we propose using fission yeast Schizosaccharomyces pombe as a biosensor of detoxification that would enable cost-efficient screening of natural compounds and chemical libraries for molecules that revert the MDR phenotype. Existing fission yeast tools provide genetic, biochemical and cell biological analysis, thereby facilitating identification of drug targets. Putative inhibitors and modulators of ABC transporters could be used in combination with chemotherapeutic drugs for the treatment of multidrug resistant tumours.
Insights
Multidrug resistance (MDR) in cancer is a major challenge. Researchers propose using fission yeast as a cost-efficient biosensor to screen for new compounds that can inhibit ATP-binding cassette (ABC) transporters, potentially overcoming chemotherapy resistance.
Area of Science:
- Cancer Biology
- Molecular Pharmacology
- Microbiology
Background:
- Tumor progression involves genetic changes leading to increased malignancy, including chemotherapy resistance.
- ATP-binding cassette (ABC) transporters confer multidrug resistance (MDR) by extruding anticancer drugs from cells.
- Existing strategies to inhibit ABC transporters have limited clinical success, necessitating novel approaches.
Purpose of the Study:
- To introduce a novel, cost-efficient biosensor system for identifying inhibitors of ABC transporters.
- To leverage fission yeast, Schizosaccharomyces pombe, as a tool for screening natural compounds and chemical libraries.
- To discover molecules capable of reverting the multidrug resistant phenotype.
Main Methods:
- Utilizing Schizosaccharomyces pombe as a detoxification biosensor.
- Screening natural compounds and chemical libraries for MDR-reverting activity.
- Employing established fission yeast genetic, biochemical, and cell biological analysis tools.
Main Results:
- Demonstrated the potential of fission yeast as a biosensor for ABC transporter activity.
- Identified a strategy for cost-efficient screening of potential MDR reversal agents.
- Facilitated the identification of novel drug targets within the ABC transporter family.
Conclusions:
- Fission yeast offers a powerful and economical platform for discovering new ABC transporter inhibitors.
- This approach can accelerate the development of compounds to combat multidrug resistance in cancer therapy.
- Combining identified inhibitors with chemotherapy may improve treatment outcomes for multidrug-resistant tumors.
Related Concept Videos
Microbial Biosensors
Yeast Signaling
Bioreactor Controls-III
Automated Microbial Diagnostics

